advertisement
Abstract #21554 Published in IGR 10-3
Comparison of daytime efficacy and safety of dorzolamide/timolol maleate fixed combination versus latanoprost
Mulaney J; Sonty S; Ahmad A; Stewart JA; Stewart WCEuropean Journal of Ophthalmology 2008; 18: 556-562
PURPOSE: To compare the 12-hour efficacy and safety of dorzolamide/timolol fixed combination (DTFC) dosed twice daily versus latanoprost dosed every evening following a timolol run-in in primary open-angle glaucoma patients. METHODS: Following a 6-week timolol run-in patients were randomized to either DTFC or latanoprost for 6 weeks and then changed to the opposite treatment for 6 weeks. At the end of the run-in, and the end of each treatment period, the intraocular pressure (IOP) was measured every 2 hours between 8:00 AM and 8:00 PM. RESULTS: Thirty-one patients completed at least one time point in both treatment periods. Both treatments reduced the IOP for the diurnal curve, and at each time point, from the timolol run-in baseline (p < 0.0001). The 12-hour IOP on timolol was 22.1 ± 2.8 mmHg, whereas on DTFC it was 18.1 ± 2.8 and latanoprost 18.3 ± 3.1 mmHg (p = 0.4). Further, there was no statistical difference in IOP between treatments at any time point (p ≤ 0.1). There was no statistical difference for any individual adverse event between treatments (p > 0.05). CONCLUSIONS: This study suggests that following a timolol run-in both DTFC and latanoprost provide comparable daytime efficacy and safety.
Dr. J. Mulaney, Central Florida Eye Associates, Lakeland, FL, USA
Classification:
11.13.2 Betablocker and carbon anhydrase inhibitor (Part of: 11 Medical treatment > 11.13 Combination therapy)
11.4 Prostaglandins (Part of: 11 Medical treatment)
